|
|
 |
|
Viewing report
|
|
|
|
Pricing & Reimbursement - Seven Major Markets Update
Datamonitor, May 2008, Pages: 119
Governments and payers across the seven major markets are implementing cost-cutting initiatives to combat escalating healthcare costs, putting even greater pressure on pharma companies. In addition to the credit crunch, ever fewer novel products are coming to market, contributing to the declining return on investment.
Scope
- Overview of P&R issues in the market today and their impact on branded Pharma
- Introduction to the current P&R tools utilized across the seven major markets to contain costs
- Analysis of each of the seven major markets, examining both the healthcare systems and the key P&R infrastructure
- Identification of trends and recommendations shaping national P&R environments
Highlights of this title
It is now a perquisite to perform pharmacoeconomic assessments early on in the drug development process and provide cost effective evaluations to ensure access to reimbursement lists
In the, US pharma companies can expect the Federal government and insurance providers to seek out negotiations to cut drug costs. Presently, Medicare is unable to negotiate drug prices with Pharma, although a Democratic government will want to amend legislation giving it more power to challenge Pharma on drug prices
Parallel trade will continue to play a role in driving down drug prices in Europe. However, as drug price differences between EU countries decreases due to reference pricing, coupled with the claw-back system imposed on pharmacies, the incentive to use parallel traded products will progressively weaken
Key reasons to purchase this title
- Gain a clear understanding of the recent changes in the P&R environment across the seven major markets and how this is impacting pharma companies
- Review recent P&R trends in the seven major markets based on Datamonitor analysis and primary research conducted with key stakeholders in the industry
- Provides analysis of todays market situation, focusing on the up coming US presidential elections and the potential impact on future P&R initiatives
Customers who bought this item also bought
Pricing and Reimbursement in Japan: Costly Healthcare System Inefficiencies increase the focus on healthcare cost containment
Pricing & Reimbursement in Europe: Can the Drive for Cost Effectiveness Overcome Cost Containment?
Pricing and Reimbursement Series: NICE its impact on the UK healthcare system and beyond
Pricing and Reimbursement in the United Arab Emirates
Drug Price/Cost Debate: Coping with Escalating Pricing Pressures
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Pricing and Reimbursement Risk and Opportunities in Pharmaceutical Deal Making
The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pharmaceutical Pricing and Reimbursement in Italy, 2008
R&D Cost Cutting: Managing Cost Containment and Safeguarding Productivity
IMS Pharma Pricing & Reimbursement Concise Guide Series The Americas
|
|
|
|
